InterCure and Cannasoul Form Strategic Partnership to Advance Cannabis Science and Pharmaceutical Innovation.
ByAinvest
Monday, Nov 3, 2025 8:33 am ET1min read
INCR--
InterCure and Cannasoul have signed a strategic investment and collaboration agreement to advance cannabis science and pharmaceutical innovation. The partnership combines InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovation. The collaboration comes as the Trump administration explores cannabis rescheduling, potentially unlocking opportunities for international operators like InterCure. InterCure will acquire a 28% ownership position in Cannasoul and has an exclusive path to increase its holdings to 51%.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet